Prediction of the responsiveness to antidepressants by DNA methylation in patients with major depression

为了阐明抗抑郁药临床疗效个体差异的DNA甲基化标志物，我们对抑郁症患者脑源性神经营养因子(BDNF)、胶质细胞源性神经营养因子(GDNF)、5-羟色胺转运体(5HTT)和5-羟色胺受体1A(5HT1A)进行了DNA甲基化分析。我们首先对帕罗西汀有反应和无反应的患者这4个基因中104个CpG位点的DNA甲基化水平进行了筛查分析。接下来，在接受帕罗西汀治疗的60名患者中，我们调查了筛选分析检测到的CpG位点DNA甲基化水平与帕罗西汀疗效之间的关系。我们在BDNF基因中检测到一个与帕罗西汀反应相关的CpG位点。

To elucidate the DNA methylation marker associated with inter-individual difference in therapeutic efficacy observed in the clinical use of antidepressants, we performed DNA methylation analysis of brain-derived neurotrophic factor (BDNF), glial cell derived neurotrophic factor (GDNF), serotonin transporter (5HTT) and Serotonin receptor 1A (5HT1A) in the patients with major depressive disorder. We first performed screening analysis of DNA methylation levels of 104 CpG sites in these 4 genes in patient with response and non-response to paroxetine. Next, in 60 patients treated with paroxetine, we investigated the association between DNA methylation level of CpG sites detected by screening analysis and efficacy of paroxetine. We detected one CpG site in BDNF gene related to response to paroxetine.